BMS rises on growth potential despite revenue declines from patent losses
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb reported on 24 January that 2012 sales ended up significantly lower than in the previous year and 2013 revenue will be lower still, but investors seemed happy with the company's guidance for this year and plans to make up for the earnings slide caused by blockbuster drug patent expirations.